Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hille

Showing results (111-120 of 119) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 119 results.
Current Medical Research and Opinion|February 10, 2007
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophyRichard B Devereux, Ulf de Faire, Frej Fyhrquist, et al.
Pharmacogenetics and Genomics|January 13, 2010
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE studyBørge G Nordestgaard, Kimmo Kontula, Marianne Benn, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 27, 2013
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trialZhihuang Hu, Ying Cheng, Hongyu Zhang, et al.
Circulation|April 20, 2005
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) studyGiovanni de Simone, Kristian Wachtell, Vittorio Palmieri, et al.
Blood Pressure|December 17, 2009
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension studySverre E Kjeldsen, Richard B Devereux, Darcy A Hille, et al.
Pediatric Blood & Cancer|July 1, 2016
A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcomaPeter M Anderson, Stefan S Bielack, Richard G Gorlick, et al.
Hypertension (Dallas, Tex. : 1979)|March 26, 2005
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophyFrej Fyhrquist, Björn Dahlöf, Richard B Devereux, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 8, 2025
Neoadjuvant radiochemotherapy in patients with high-risk locally advanced cervical cancer-results of a clinical seriesS Donath, M A Schirmer, F Bremmer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 4, 2016
[Not Available]Thomas G Wendt, G Gademann, C Pambor, et al.
Pageof 12

Showing results (111-120 of 119) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 119 results.
Current Medical Research and Opinion|February 10, 2007
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophyRichard B Devereux, Ulf de Faire, Frej Fyhrquist, et al.
Pharmacogenetics and Genomics|January 13, 2010
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE studyBørge G Nordestgaard, Kimmo Kontula, Marianne Benn, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 27, 2013
Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trialZhihuang Hu, Ying Cheng, Hongyu Zhang, et al.
Circulation|April 20, 2005
Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) studyGiovanni de Simone, Kristian Wachtell, Vittorio Palmieri, et al.
Blood Pressure|December 17, 2009
Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension studySverre E Kjeldsen, Richard B Devereux, Darcy A Hille, et al.
Pediatric Blood & Cancer|July 1, 2016
A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcomaPeter M Anderson, Stefan S Bielack, Richard G Gorlick, et al.
Hypertension (Dallas, Tex. : 1979)|March 26, 2005
Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophyFrej Fyhrquist, Björn Dahlöf, Richard B Devereux, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|January 8, 2025
Neoadjuvant radiochemotherapy in patients with high-risk locally advanced cervical cancer-results of a clinical seriesS Donath, M A Schirmer, F Bremmer, et al.
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 4, 2016
[Not Available]Thomas G Wendt, G Gademann, C Pambor, et al.
Pageof 12